Radiation dosimetry and biodistribution of ^{11}C -ABP688 measured in healthy volunteers

Journal Article

Author(s):

Treyer, Valerie; Streffer, Johannes; Ametamey, Simon M.; Bettio, Andrea; Bläuenstein, Peter; Schmidt, Mark; Gasparini, Fabrizio; Fischer, Uta; Hock, Christoph; Buck, Alfred

Publication date:

2008-04-01

Permanent link:

<https://doi.org/10.3929/ethz-b-000082930>

Rights / license:

[In Copyright - Non-Commercial Use Permitted](#)

Originally published in:

European Journal of Nuclear Medicine and Molecular Imaging 35(4), <https://doi.org/10.1007/s00259-007-0638-4>

Radiation dosimetry and biodistribution of ^{11}C -ABP688 measured in healthy volunteers

Valerie Treyer · Johannes Streffer ·
Simon M. Ametamey · Andrea Bettio ·
Peter Bläuenstein · Mark Schmidt ·
Fabrizio Gasparini · Uta Fischer ·
Christoph Hock · Alfred Buck

Received: 16 March 2007 / Accepted: 9 October 2007 / Published online: 11 December 2007
© Springer-Verlag 2007

Abstract

Introduction In this study, we assessed the whole-body biodistribution and radiation dosimetry of the new glutamatergic ligand ^{11}C -ABP688. This ligand binds specifically to the metabotropic glutamatergic receptor of subtype 5 (mGluR5).

Materials and methods The study included five healthy male volunteers aged 20–29 years. After intravenous injection of 240–260 MBq, a series of four to ten whole-body positron emission tomography/computed tomography scans were initiated, yielding 60–80 min of data. Residence times were then calculated in the relevant organs, and the software packages Mirdose and Olinda were used to calculate the absorbed radiation dose and the effective dose equivalent.

Results Of the excreted ^{11}C activity at 1 hour, approximately 80% were eliminated via the hepato-biliary pathway and 20% through the urinary tract. The absorbed dose (mGy/MBq) was highest in the liver ($1.64 \text{ E }^{-2} \pm 5.08 \text{ E }^{-3}$), gallbladder ($8.13 \text{ E }^{-3} \pm 5.6 \text{ E }^{-3}$), and kidneys ($7.27 \text{ E }^{-3} \pm 2.79 \text{ E }^{-3}$). The effective dose equivalent was $3.68 \pm 0.84 \text{ microSv/MBq}$. Brain uptake in the areas with high mGluR5 density was 2–3 (SUV). The agreement between the values obtained from Mirdose and the Olinda was excellent.

Conclusion ^{11}C -ABP688 is a very promising ligand for the investigation of mGluR5 receptors in humans. Brain uptake is high and the effective dose equivalent so low that serial examinations in the same subject seem feasible.

Keywords ^{11}C -ABP688 · Metabotropic glutamate receptor subtype 5 · Whole-body PET/CT · Dosimetry

V. Treyer · A. Buck (✉)
PET Center, Division of Nuclear Medicine,
University Hospital Zurich,
Rämistrasse 100,
8091 Zurich, Switzerland
e-mail: fred.buck@usz.ch

J. Streffer · U. Fischer · C. Hock
Division of Psychiatry Research, University of Zurich,
Zurich, Switzerland

S. M. Ametamey · A. Bettio · P. Bläuenstein
Department of Chemistry and Applied Biosciences of ETH,
Center for Radiopharmaceutical Science of ETH, PSI and USZ,
Zurich, Switzerland

M. Schmidt
Novartis Pharma AG,
Basel, Switzerland

F. Gasparini
Novartis Institutes for Biomedical Research,
Basel, Switzerland

Introduction

Since the cloning of the first metabotropic glutamate receptor (mGlu1) in 1991 [1], seven additional subtypes of this receptor (mGlu2–8) have been cloned. For the mGluR5 receptor subtype, based on the wide and consistent effects of selective noncompetitive allosteric antagonists such as 2-methyl-6-(phenylethynyl)pyridine in animal models for anxiety [2, 3], it has been hypothesized that this receptor could be a valuable target for the treatment of anxiety-related disorders [4–6]. The development of positron emission tomography (PET) tracers for the glutamatergic receptors proved difficult. Only recently, a series of PET ligands, allowing the in vivo imaging in rhesus monkeys, has been described [7]. Recently, we identified ^{11}C -ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-

Fig. 1. Whole-body CT and PET 60–70 min after injection of 260 MBq ^{11}C -ABP688

2-enone- O -[^{11}C]-methyl-oxime) as a very promising ligand to investigate mGluR5 [8]. This compound is a highly selective allosteric antagonist of the mGluR5 receptor in vitro, and initial studies have demonstrated a high selectivity for mGluR5 receptors in vivo [8]. The purpose of this study was to evaluate the whole-body biodistribution and radiation dosimetry of ^{11}C -ABP688 in humans using whole-body PET/computed tomography (CT).

Materials and methods

Synthesis of ^{11}C -ABP688

The synthesis of ^{11}C -ABP688 has been described in detail elsewhere [8]. Briefly, desmethyl ABP688 was reacted with ^{11}C -methyl iodide produced from the GE PET trace system at 90°C for 5 min. The product was purified by semi-preparative high-performance liquid chromatography using a reversed-phase column. Formulation of ^{11}C -ABP688 for in vivo administration was accomplished using 0.15 M phosphate buffer and ethanol. The average specific activity was 232 GBq/ μmol (SD $\pm$ 72.56).

Subjects

The study included five healthy male subjects, aged 24.5 ± 3.2 (range, 20–29 years). All subjects gave their written

informed consent, and the study was approved by the local ethics committee for radiological research in Zurich.

Positron emission tomography

The subjects were positioned supine in the PET/CT scanner (Discovery LS and Discovery RX, GE Healthcare, Milwaukee). To correct for photon attenuation and for anatomical reference, a low dose CT scan was performed before tracer administration. After the injection of 240–260 MBq ^{11}C -ABP688, a series of four to ten whole-body scans was initiated. Each scan covered the body from the head to the knees and consisted of several bed positions (15 cm field of view). In each bed position, data were acquired for 1–2 min in 2D mode. Total acquisition time was 60–80 min. The data were then reconstructed on a 128×128 matrix (slice thickness, 4.25 mm) and corrected for photon attenuation using the CT scan. Volumes of interest were placed over different organs using the software PMOD (<http://www.pmod.com>) and the CT scan for anatomical reference, and the time course of radioactivity (Bq/ml) was calculated. Because the output from the commercial reconstruction software was a decay-corrected whole-body data set and dosimetry requires the actual, non-decay-corrected time-course of organ radioactivity, the decay correction was removed from each time-activity curve, considering also the actual acquisition time of each field of view.

Dosimetry

The calculation of dosimetry requires the area under the time-activity curves, which was calculated as follows: If possible, a declining monoexponential was fitted to the data and extrapolated to time-point zero and infinity. If monoexponential fitting was not appropriate, the actual data were numerically integrated to the end point of the scan. After this time, it was assumed that the activity dropped with the

Fig. 2. Typical tissue time-activity curves of non-decay-corrected ^{11}C activity

Table 1. Residence times (hours) of ^{11}C -ABP688

	Subject 1	Subject 2	Subject 3	Subject 4	Subject 5	Mean	SD
Muscles	1.314E-01	9.165E-02	1.317E-01	1.276E-01	1.157E-01	1.196E-01	1.692E-02
Liver	1.434E-01	6.047E-02	8.975E-02	8.431E-02	9.687E-02	9.496E-02	3.034E-02
Bone marrow	2.404E-02	1.514E-02	1.547E-02	1.634E-02	1.759E-02	1.772E-02	3.661E-03
Small intestine	2.067E-02	1.467E-02	1.689E-02	1.907E-02	1.504E-02	1.727E-02	2.582E-03
Brain	1.845E-02	1.293E-02	1.679E-02	1.591E-02	1.259E-02	1.533E-02	2.524E-03
Kidney	1.043E-02	4.181E-03	6.838E-03	3.693E-03	8.490E-03	6.726E-03	2.851E-03
Urinary bladder	8.220E-03	1.676E-03	5.244E-03	3.364E-03	8.135E-03	5.328E-03	2.892E-03
Lung	2.796E-03	2.235E-03	2.829E-03	2.363E-03	2.925E-03	2.630E-03	3.089E-04
Gallbladder	5.118E-04	1.633E-03	3.241E-03	7.038E-05	6.041E-03	2.299E-03	2.423E-03
Heartwall	2.283E-03	1.588E-03	2.055E-03	1.959E-03	1.826E-03	1.942E-03	2.590E-04
Pancreas	1.414E-03	5.517E-04	1.199E-03	1.243E-03	1.611E-03	1.204E-03	3.990E-04
Spleen	1.335E-03	6.712E-04	1.320E-03	9.744E-04	1.155E-03	1.091E-03	2.765E-04
Testes	2.120E-04	1.825E-04	2.381E-04	1.360E-04	2.057E-04	1.948E-04	3.839E-05
Thyroid	1.873E-04	1.100E-04	1.210E-04	1.426E-04	1.301E-04	1.382E-04	2.994E-05

physical half-time of ^{11}C . As this assumption neglects clearance of residual activity from the organ, the effective radiation dose will be somewhat overestimated. The residence time in the different organs was calculated by dividing the time integrals by the injected amount of activity. The mean absorbed dose was subsequently calculated using the software Mirdose3 [9] and Windows 98 and for comparison with the software Olinda [10] and Windows 2000.

It is essential to use Mirdose3 with Windows 98 or 95. The combination of Mirdose3 and Windows XP yields much lower doses because the S value table is not read correctly. It shows that only the self-absorption doses (identical source

and target organ) are considered while all other S values (target organ different from source organs) are zero.

Results

Coronal sections of a typical whole-body PET are demonstrated in Fig. 1. Most of the ^{11}C activity is found in the gallbladder and in the bile secreted in the small intestine. The figure illustrates the primarily hepatobiliary excretion of the ^{11}C activity. An illustrative set of tissue time-activity curves is depicted in Fig. 2. In the liver, kidneys, and brain, the clearance of activity after the initial increase was

Table 2. Absorbed dose estimates (mGy/MBq) and effective dose equivalent (mSv/MBq) for ^{11}C -ABP688

	Subject 1	Subject 2	Subject 3	Subject 4	Subject 5	Mean MIRD	SD MIRD	Mean Olinda	SD Olinda
Liver	2.44E-02	1.05E-02	1.56E-02	1.45E-02	1.68E-02	1.64E-02	5.08E-03	1.64E-02	5.12E-03
Gallbladder wall	5.17E-03	5.61E-03	1.02E-02	2.75E-03	1.69E-02	8.13E-03	5.60E-03	8.12E-03	5.55E-03
Kidneys	1.10E-02	4.64E-03	7.32E-03	4.50E-03	8.87E-03	7.27E-03	2.79E-03	7.27E-03	2.79E-03
Small intestine	7.20E-03	4.94E-03	5.86E-03	6.40E-03	5.34E-03	5.95E-03	8.90E-04	5.94E-03	8.87E-04
Pancreas	5.90E-03	2.58E-03	4.82E-03	4.77E-03	6.01E-03	4.82E-03	1.38E-03	4.85E-03	1.39E-03
Urinary bladder wall	6.26E-03	6.08E-03	4.18E-03	2.93E-03	6.09E-03	5.11E-03	1.49E-03	4.23E-03	2.01E-03
Brain	4.33E-03	3.05E-03	3.95E-03	3.74E-03	2.99E-03	3.61E-03	5.81E-04	3.62E-03	5.90E-04
Red marrow	3.46E-03	2.12E-03	2.40E-03	2.44E-03	2.60E-03	2.60E-03	5.09E-04	2.61E-03	5.14E-04
Heart wall	3.17E-03	2.00E-03	2.67E-03	2.54E-03	2.51E-03	2.58E-03	4.18E-04	2.59E-03	4.33E-04
Thyroid	2.84E-03	1.70E-03	1.98E-03	2.20E-03	2.04E-03	2.15E-03	4.25E-04	2.14E-03	4.09E-04
Adrenals	2.49E-03	1.24E-03	1.79E-03	1.64E-03	1.89E-03	1.81E-03	4.54E-04	1.83E-03	4.65E-04
Muscle	1.95E-03	1.26E-03	1.81E-03	1.73E-03	1.67E-03	1.68E-03	2.59E-04	1.69E-03	2.64E-04
Testes	1.80E-03	1.47E-03	2.01E-03	1.35E-03	1.80E-03	1.69E-03	2.69E-04	1.68E-03	2.82E-04
ULI wall	2.03E-03	1.22E-03	1.62E-03	1.58E-03	1.63E-03	1.62E-03	2.87E-04	1.62E-03	2.91E-04
Lungs	1.21E-03	1.19E-03	1.62E-03	1.45E-03	1.65E-03	1.42E-03	2.18E-04	1.57E-03	2.69E-04
Stomach	1.29E-03	7.16E-04	1.03E-03	9.61E-04	1.05E-03	1.01E-03	2.06E-04	1.03E-03	2.15E-04
LLI wall	1.13E-03	7.03E-04	9.55E-04	9.38E-04	9.32E-04	9.32E-04	1.52E-04	9.33E-04	1.52E-04
Effective dose equivalent	4.53E-03	2.63E-03	3.79E-03	3.02E-03	4.42E-03	3.68E-03	8.40E-04	3.70E-03	8.69E-04

adequately fitted by a decaying monoexponential. In the gall bladder, the small intestine, and the urinary bladder, the time-course was more protracted. Of the excreted ^{11}C activity at 1 h, approximately 80% were eliminated via the hepato-biliary pathway and 20% through the urinary tract. The residence times are summarized in Table 1. Because of the large mass, it was largest in the muscles, followed by liver, bone marrow, and small intestine. The smallest values were found in the testes and the thyroid gland. The mean absorbed dose in the various organs is reported in Table 2. The highest absorbed dose was present in the liver, followed by gall bladder wall, kidneys, and small intestine. The agreement between the values calculated with the softwares Mirdose3 and Olinda in the different organs was, in general, excellent. A small discrepancy was observed in the urinary bladder (Olinda, 17% lower) and the lungs (Olinda, 10% larger). Nevertheless, the mean effective dose equivalent was almost identical. The distribution of ^{11}C -ABP688 in the brain is demonstrated in Fig. 3a. High tracer uptake is found in the cortex, especially in the mediotemporal area; less uptake was present in the thalamus, and the lowest tracer accumulation was present in the cerebellum. Corresponding tissue time-activity curves are illustrated in Fig. 3b.

Fig. 3. ^{11}C -ABP688 distribution in the brain 40–50 min after injections (a) and decay-corrected tissue time-activity curves of several brain areas (b). The data were taken from another study in which the brain distribution of ^{11}C -ABP688 was evaluated [11]

Discussion

The presented data demonstrate a promising distribution and kinetics of ^{11}C -ABP688 for the evaluation of mGluR5. Brain uptake is high, which results in high-quality images and good statistics for quantification. The pattern of tracer distribution in the brain is similar to the one described in our recent animal [8] and human study [11].

The study demonstrates that the main route of elimination of the tracer is the hepato-biliary pathway followed by the urinary tract. This is not surprising given the lipophilicity of ^{11}C -ABP688. As a consequence, the liver and the gall bladder are the organs with the highest absorbed dose.

One possible error in the dosimetry could result from the monoexponential fitting, which was applied in this study. Especially in organs with a low retention of the tracer, there will be an early perfusion phase that is missed in whole-body scanning. To estimate this error, we assumed that this perfusion phase would add 20% to the residence times of myocardium, kidney, liver, lung, and bone marrow. The recalculation then revealed, that this 20% increase would add only 11% to the mean effective dose equivalent ($4.10\text{E-}03 \pm 9.80\text{E-}04$ vs $3.70\text{E-}03 \pm 8.69\text{E-}04$ mSv/MBq).

Concerning radiation protection, ^{11}C -ABP688 compares favorably with other receptor tracers. For example, the effective dose equivalent is lower than the 6.7 microSv/MBq reported for ^{11}C -raclopride, a marker to measure dopaminergic D2 receptors [12] and considerably lower than the 19 microSv/MBq estimated for the tracer ^{18}F -Fluoro-A-85380, a candidate for the investigation of nicotinic receptors [13]. The injected amount of about 250 MBq ^{11}C -ABP688 resulted in an effective dose equivalent of 0.9–1.1 mSv. This low value allows multiple serial examinations of the same subject. For instance, an upper limit of the radiation burden of 5 mSv would allow the injection of 1,000 MBq ^{11}C -ABP688, including the addition 11% increase caused by the possible underestimation because of monoexponential fitting. On modern scanners operated in 3D mode, 200 MBq are sufficient for a single scan, meaning that one subject could be investigated on five different occasions. This opens the possibility of very efficient interventional studies, for instance, receptor occupancy studies with new drugs aimed at interfering with the mGluR5 receptor.

Whole-body PET has been recently used for dosimetry studies in humans by several groups [12–16]. This became possible only recently with the latest generation of scanners that allow whole-body scanning with adequate temporal resolution. In the past, most dosimetry calculations were done with the software Mirdose3. Because of incompatibilities with newer operating systems, the code was rewritten and was made available as Olinda [10], which may become more widespread in the future. The excellent

agreement of the values calculated with both programs indicates that they are interchangeable.

Conclusion

^{11}C -ABP688 is a very promising ligand for the investigation of mGluR5 receptors in humans. Brain uptake is high and the effective dose equivalent so low that serial examinations in the same subject seem feasible.

Acknowledgment Valerie Treyer was supported by the Swiss National Science Foundation. The study was sponsored by Novartis, Basel, and supported by the 51NF40-111381 (NCCR Neuro) and EU LSHM-CT-2003-503330 (APODIS). We thank Esmeralda Gruber for the excellent clinical study support.

References

- Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S. Sequence and expression of a metabotropic glutamate receptor. *Nature* 1991;349(6312):760–5.
- Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. *Neuropharmacology* 1999;38(10):1493–503.
- Kuhn R, Pagano A, Stoehr N, Vranesic I, Flor PJ, Lingenhohl K, et al. In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article. *Amino Acids* 2002;23(1–3):207–11.
- Spooren W, Gasparini F. mGlu5 receptor antagonists: a novel class of anxiolytics? *Drug News Perspect* 2004;17:251–7.
- Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. *J Pharmacol Exp Ther* 2000;295(3):1267–75.
- Tataczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. *Br J Pharmacol* 2001;132(7):1423–30.
- Hamill TG, Krause S, Ryan C, Bonnefous C, Govek S, Seiders TJ, et al. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. *Synapse* 2005;56(4):205–16.
- Ametamey SM, Kessler LJ, Honer M, Wyss MT, Hintermann S, Auberson YP, et al. Radiosynthesis and preclinical evaluation of [^{11}C]-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5 (mGluR5). *J Nucl Med* 2005;47:698–705.
- Stabin MG. MIRDose: personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med* 1996;37(3):538–46.
- Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med* 2005;46(6):1023–7.
- Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, et al. Human PET studies of metabotropic glutamate receptor subtype 5 with ^{11}C -ABP688. *J Nucl Med* 2007;48(2):247–52.
- Ribeiro MJ, Ricard M, Bourgeois S, Lievre MA, Bottlaender M, Gervais P, et al. Biodistribution and radiation dosimetry of [^{11}C] raclopride in healthy volunteers. *Eur J Nucl Med Mol Imaging* 2005;32(8):952–8.
- Bottlaender M, Valette H, Roumenov D, Dolle F, Coulon C, Ottaviani M, et al. Biodistribution and radiation dosimetry of ^{18}F -fluoro-A-85380 in healthy volunteers. *J Nucl Med* 2003;44(4):596–601.
- Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED. Whole-body radiation dosimetry of 2- ^{18}F -fluoro-A-85380 in human PET imaging studies. *Nucl Med Biol* 2005;32(8):869–74.
- Seneca N, Andree B, Sjöholm N, Schou M, Pauli S, Mozley PD, et al. Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[^{18}F] FMeNER-D2 in non-human primates. *Nucl Med Commun* 2005;26(8):695–700.
- Slifstein M, Hwang DR, Martinez D, Ekelund J, Huang Y, Hackett E, et al. Biodistribution and Radiation dosimetry of the dopamine D2 Ligand ^{11}C -raclopride determined from human whole-body PET. *J Nucl Med* 2006;47(2):313–9.